Isletopathy in type 2 diabetes mellitus: Implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress

被引:63
|
作者
Hayden, Melvin R. [1 ]
Sowers, James R.
机构
[1] Univ Missouri, Sch Med, Dept Internal Med, Columbia, MO 65211 USA
[2] Univ Missouri, Sch Med, Dept Diabet Endocrinol & Metab, Columbia, MO 65211 USA
[3] Univ Missouri, Sch Med, Dept Pharmacol & Physiol, Columbia, MO 65211 USA
[4] Univ Missouri, Sch Med, Dept Diabet, Columbia, MO 65211 USA
[5] Univ Missouri, Sch Med, Cardiovasc Dis Res Grp, Columbia, MO 65211 USA
关键词
D O I
10.1089/ars.2007.1610
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review focuses primarily on islet structural and functional changes related to an activated islet renin angiotensin system (RAS), islet oxidative-redox imbalance, the concurrence of islet fibrosis (pericapillary, intra- and peri-islet), and islet amyloid deposition ( pericapillary, intra- and peri-islet). The islet-acinar-portal vascular pathway and the emerging important anatomical and functional region, the islet-exocrine interface, are also discussed. Because there is an associated histopathological islet disease in type 2 diabetes mellitus (T2DM), the term isletopathy is discussed in detail. The isletopathy in T2DM is equally important as the other complications of diabetes. Special stains and special lighting ( bright field and crossed polarized light) are utilized, along with light and transmission electron microscopy, in order to better understand islet structural remodeling in T2DM. The importance of an isletopathy in T2DM is supported by numerous remodeling changes within the islet and the islet-exocrine interface. While some of the structural findings are only preliminary observations, additional investigation in this area should lead to the development of new pathophysiological concepts and new therapies regarding the prevention and treatment of T2DM.
引用
收藏
页码:891 / 910
页数:20
相关论文
共 50 条
  • [1] Islet amyloid and type 2 diabetes mellitus
    Höppener, JWM
    Ahrén, B
    Lips, CJM
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (06): : 411 - 419
  • [2] ISLET AMYLOID POLYPEPTIDE, ISLET AMYLOID, AND DIABETES MELLITUS
    Westermark, Per
    Andersson, Arne
    Westermark, Gunilla T.
    PHYSIOLOGICAL REVIEWS, 2011, 91 (03) : 795 - 826
  • [3] Role of islet amyloid in type 2 diabetes mellitus
    Höppener, JWM
    Lips, CJM
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (5-6): : 726 - 736
  • [4] ISLET AMYLOID, ISLET-AMYLOID POLYPEPTIDE, AND DIABETES-MELLITUS
    JOHNSON, KH
    OBRIEN, TD
    BETSHOLTZ, C
    WESTERMARK, P
    NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (08): : 513 - 519
  • [5] Pancreatic Angiopathy Associated With Islet Amyloid and Type 2 Diabetes Mellitus
    Ling, Wei
    Huang, Yi
    Huang, Yan-Mei
    Shen, Jian
    Wang, Shan-Huan
    Zhao, Hai-Lu
    PANCREAS, 2020, 49 (09) : 1232 - 1239
  • [6] Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?
    A. Clark
    M. R. Nilsson
    Diabetologia, 2004, 47 : 157 - 169
  • [7] Role of islet amyloid in type 2 diabetes mellitus:: consequence or cause?
    Höppener, JWM
    Nieuwenhuis, MG
    Vroom, TM
    Ahrén, B
    Lips, CJM
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2002, 197 (1-2) : 205 - 212
  • [8] Clinicopathological characteristics of islet amyloid in Type 2 diabetes mellitus.
    Zhao, H
    Lai, FMM
    Tong, PCY
    Tomlinson, B
    Chan, JCN
    DIABETOLOGIA, 2003, 46 : A157 - A157
  • [9] Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology
    Jaikaran, ETAS
    Clark, A
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2001, 1537 (03): : 179 - 203
  • [10] Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?
    Clark, A
    Nilsson, MR
    DIABETOLOGIA, 2004, 47 (02) : 157 - 169